Formulary Search
Search Results : Lipid modification (Icosapent - Lipid modification)
Show Icon and Status Keys
- Capsules
- Tablets
- Chewable tablets
To be reserved for use in patients who cannot swallow tablets.
Chewable tablets should be used in preference to atorvastatin oral suspension.
Not suitable for administration via feeding tube.
- Tablets
Only as add-on therapy for patients already on ezetimibe. Use the combination product (bempedoic acid with ezetimibe) in new patients.
Bempedoic acid should not be considered for patients taking a statin as per NICE TA694 recommendations.
- Tablets
Bempedoic acid should not be considered for patients taking a statin as per NICE TA694 recommendations.
- Tablets
- Capsules
Doses of 80mg may be achieved by taking a 40mg capsule twice a day.
- Modified release tablets
Capsules are the preferred formulation and should be used in preference to the modified release tablets unless:
- capsules are not suitable
- an 80mg dose is required and a 40mg capsule twice a day is not suitable
- Subcutaneous injection (sc)
Prescribing in secondary care is commissioned by NHSE
- Tablets
- Tablets
- Oro-dispersible tablets
To be reserved for use in patients who cannot swallow tablets.
Orodispersible tablets should be used in preference to unlicensed liquid formulations.
Not suitable for administration via feeding tube.
- Capsules
Rosuvastatin capsules are considerably more expensive and should not be prescribed.
- Tablets
- Modified release tablets
- Tablets
- Tablets
- Tablets
- Sachets (powder)
- Capsules
- Tablets
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
- Capsules
- Tablets
- Not Specified
This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.